Selected article for: "immune system and patient management"

Author: Al‐Ani, Aysha H.; Prentice, Ralley E.; Rentsch, Clarissa A.; Johnson, Doug; Ardalan, Zaid; Heerasing, Neel; Garg, Mayur; Campbell, Sian; Sasadeusz, Joe; Macrae, Finlay A.; Ng, Siew C.; Rubin, David T.; Christensen, Britt
Title: Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient
  • Cord-id: 77903fld
  • Document date: 2020_5_26
  • ID: 77903fld
    Snippet: BACKGROUND: The current COVID‐19 pandemic, caused by SARS‐CoV‐2, has emerged as a public health emergency. All nations are seriously challenged as the virus spreads rapidly across the globe with no regard for borders. The primary management of IBD involves treating uncontrolled inflammation with most patients requiring immune‐based therapies. However, these therapies may weaken the immune system and potentially place IBD patients at increased risk of infections and infectious complicatio
    Document: BACKGROUND: The current COVID‐19 pandemic, caused by SARS‐CoV‐2, has emerged as a public health emergency. All nations are seriously challenged as the virus spreads rapidly across the globe with no regard for borders. The primary management of IBD involves treating uncontrolled inflammation with most patients requiring immune‐based therapies. However, these therapies may weaken the immune system and potentially place IBD patients at increased risk of infections and infectious complications including those from COVID‐19. AIM: To summarise the scale of the COVID‐19 pandemic, review unique concerns regarding IBD management and infection risk during the pandemic and assess COVID‐19 management options and drug interactions in the IBD population. METHODS: A literature review on IBD, SARS‐CoV‐2 and COVID‐19 was undertaken and relevant literature was summarised and critically examined. RESULTS: IBD patients do not appear to be more susceptible to SARS‐CoV‐2 infection and there is no evidence of an association between IBD therapies and increased risk of COVID‐19. IBD medication adherence should be encouraged to prevent disease flare but where possible high‐dose systemic corticosteroids should be avoided. Patients should exercise social distancing, optimise co‐morbidities and be up to date with influenza and pneumococcal vaccines. If a patient develops COVID‐19, immune suppressing medications should be withheld until infection resolution and if trial medications for COVID‐19 are being considered, potential drug interactions should be checked. CONCLUSION: IBD patient management presents a challenge in the current COVID‐19 pandemic. The primary focus should remain on keeping bowel inflammation controlled and encouraging medication adherence.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and activity report: 1
    • abdominal pain and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • abdominal pain and acute respiratory illness: 1, 2, 3, 4, 5, 6, 7, 8
    • abdominal pain and local protocol: 1, 2
    • abdominal pain and low infection: 1, 2, 3
    • abdominal pain and lung injury: 1, 2, 3, 4, 5
    • acid testing and acute respiratory illness: 1, 2, 3
    • acid testing and low infection: 1, 2, 3, 4, 5
    • acid testing and lung injury: 1, 2, 3
    • activity report and lung injury: 1, 2
    • acute ards respiratory distress syndrome and local protocol: 1, 2, 3
    • acute ards respiratory distress syndrome and long incubation: 1
    • acute ards respiratory distress syndrome and low infection: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute ards respiratory distress syndrome and lung field: 1, 2, 3
    • acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
    • acute ards respiratory distress syndrome and lung injury perpetuate: 1
    • acute pneumonia pneumonitis and lung injury: 1, 2